EP08.01-032 Sintilimab in Combination with Anlotinib in NSCLC Patients with Uncommon EGFR Mutations: A Phase II, Single-arm, Prospective Study
Journal of thoracic oncology（2022）
Key words
NSCLC patients,immunotherapy,uncommon EGFR mutation
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined